Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Bièche

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 2024
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working GroupM F Mosele, C B Westphalen, A Stenzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2020
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working GroupF Mosele, J Remon, J Mateo, et al.
Oncogene|August 4, 2015
TRM6/61 connects PKCα with translational control through tRNAi(Met) stabilization: impact on tumorigenesisF Macari, Y El-Houfi, G Boldina, et al.
British Journal of Cancer|June 9, 1999
European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables. Breast Cancer Somatic Genetics ConsortiumV Launonen, K Laake, P Huusko, et al.
Genes, Chromosomes & Cancer|June 24, 1999
Loss of heterozygosity at 11q23.1 and survival in breast cancer: results of a large European study. Breast Cancer Somatic Genetics ConsortiumK Laake, V Launonen, D Niederacher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 29, 2013
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT networkM Beau-Faller, N Prim, A-M Ruppert, et al.
British Journal of Cancer|April 26, 2014
Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trialC Le Tourneau, X Paoletti, N Servant, et al.
ESMO Open|April 17, 2021
Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trialE de Guillebon, M Jimenez, L Mazzarella, et al.
ESMO Open|December 30, 2025
HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomasD M Filippini, B Cabarrou, C Dupain, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classificationK Rahmani Narj Abadi, C Dupain, I Guillou, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 2024
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working GroupM F Mosele, C B Westphalen, A Stenzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2020
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working GroupF Mosele, J Remon, J Mateo, et al.
Oncogene|August 4, 2015
TRM6/61 connects PKCα with translational control through tRNAi(Met) stabilization: impact on tumorigenesisF Macari, Y El-Houfi, G Boldina, et al.
British Journal of Cancer|June 9, 1999
European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables. Breast Cancer Somatic Genetics ConsortiumV Launonen, K Laake, P Huusko, et al.
Genes, Chromosomes & Cancer|June 24, 1999
Loss of heterozygosity at 11q23.1 and survival in breast cancer: results of a large European study. Breast Cancer Somatic Genetics ConsortiumK Laake, V Launonen, D Niederacher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 29, 2013
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT networkM Beau-Faller, N Prim, A-M Ruppert, et al.
British Journal of Cancer|April 26, 2014
Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trialC Le Tourneau, X Paoletti, N Servant, et al.
ESMO Open|April 17, 2021
Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trialE de Guillebon, M Jimenez, L Mazzarella, et al.
ESMO Open|December 30, 2025
HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomasD M Filippini, B Cabarrou, C Dupain, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classificationK Rahmani Narj Abadi, C Dupain, I Guillou, et al.
Pageof 10